What Clinicians Want to Know About Toxicity Considerations Associated with BTK Inhibitors

Dr Nicole Lamanna from the Columbia University Herbert Irving Comprehensive Cancer Center in New York, New York, and Dr William G Wierda from The University of Texas MD Anderson Cancer Center in Houston, Texas, discuss the spectrum of toxicities associated with BTK inhibitors and strategies for their mitigation and management for patients with chronic lymphocytic leukemia and mantle cell lymphoma.

Episode metadata supplied by the publisher feed · Published Sep 22, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

What Clinicians Want to Know About Toxicity Considerations Associated with BTK Inhibitors

0:00 1:02:44

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Hematologic Oncology Update?

This episode is 1 hour and 2 minutes long.

When was this Hematologic Oncology Update episode published?

This episode was published on September 22, 2023.

Can I download this Hematologic Oncology Update episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!